1. 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor. (9th November 2020) Authors: Hong, David; Clarke, Jeffrey; Johanns, Tanner; Kebriaei, Partow; Heymach, John; Galal, Ahmed; Saibil, Samuel; Sacher, Adrian; Brophy, Francine; Betts, Gareth; Bath, Natalie; William, Spinner; Tipping, Alex; Tucci, Jessica; Luke, Raymond; Trivedi, Trupti; Lin, Quan; Navenot, Jean-Marc; Fracasso, P... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor. (9th November 2020) Authors: Hong, David; Clarke, Jeffrey; Johanns, Tanner; Kebriaei, Partow; Heymach, John; Galal, Ahmed; Saibil, Samuel; Sacher, Adrian; Brophy, Francine; Betts, Gareth; Bath, Natalie; William, Spinner; Tipping, Alex; Tucci, Jessica; Luke, Raymond; Trivedi, Trupti; Lin, Quan; Navenot, Jean-Marc; Fracasso, P... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗